Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
Regeneron (REGN) stock rose 12% after Q3 2026 earnings beat estimates, with revenue up 36% YoY to $5.1B and EPS up 70% to $20.07. Growth driven by Dupixent (Sanofi collaboration) and Eylea HD. Guidance raised, $2.3B in stock buybacks. Moderna (MRNA) down 2%, Merck (MRK) up 1%, Pfizer (PFE) up 0.7%.
How this was made
The 30-second read
Why it matters
Regeneron’s earnings beat and raised margin guidance are immediate drivers, while the November FDA decision on cemdisiran is the next key event that can extend or reverse the post-earnings momentum.
Market read
Traders can act on Regeneron’s earnings and guidance-driven repricing and monitor the upcoming FDA catalyst, while the other names are mostly relative-performance context.
What to watch
The article flags concentration risk (Sanofi and Bayer reliance) and ongoing regulatory and litigation overhangs, which could cap upside even after an earnings beat.
Background
The piece attributes Regeneron’s outperformance to a strong Q3 driven by Dupixent profit-share economics with Sanofi, record Eylea HD and Libtayo sales, and guidance upgrades, while Moderna, Merck, and Pfizer move more modestly.
Ticker impact
Regeneron reported Q3 2026 revenue up 36% to $5.1B and raised 2026 adjusted gross margin guidance to ~86% after a 12% surge.
Likely continued upward pressure as traders price in sustained Dupixent collaboration revenue and the upcoming FDA decision catalyst.
The article provides concrete Q3 beat figures, guidance changes, and a clear next binary FDA event (cemdisiran) that can extend the earnings-driven re-rating.
Sanofi’s Dupixent net sales rose 35% to $6.5B, and the article links the profit-share mechanics to Regeneron’s collaboration revenue jump.
Likely modest positive bias as investors infer durable Dupixent demand and collaboration profitability.
The piece reports Sanofi’s Dupixent sales and repayment/guidance context, but it does not present Sanofi-specific guidance or a standalone Sanofi catalyst beyond the partnership.
Moderna shares are down 2% in the session, with the article framing weakness versus Regeneron’s strength.
Likely limited follow-through unless additional Moderna catalysts emerge, as this article provides no new Moderna operational update.
The article states the stock slide and general context, but does not disclose a fresh Moderna earnings/guidance or regulatory/product event.
Merck shares are up 1% after an October 29 quarterly report that beat expectations and raised its profit outlook.
Likely mild upward bias as the market continues to digest the raised profit outlook.
The article provides the beat and outlook raise, but it is not clear whether any new Merck-specific information is disclosed beyond what was already reported on October 29.
Pfizer shares tick up 0.7%, with the article noting its most recent quarterly report came out August 4.
Likely range-bound absent a new Pfizer-specific disclosure, since the article does not add fresh fundamentals.
The article provides only a small price change and a dated reference to the last quarterly report, without new guidance, product, or regulatory updates.
Market effects
Reinforces healthcare as a relative safe haven during tech weakness, with biotech-specific catalysts (FDA timing) driving dispersion.
Primarily US large-cap biotech and pharma sentiment; limited direct cross-region spillover described.
Dupixent and Eylea franchise strength is globally relevant, but the article’s catalysts are US-listed and FDA-timed.
Counterpoint
The rally may be overly dependent on partnership economics (Sanofi/Bayer profit shares) and could fade if pricing pressure or biosimilar competition accelerates.
Key entities
- companyRegeneron Pharmaceuticals
Q3 2026 revenue and EPS beat, raised 2026 adjusted gross margin guidance, and awaits November FDA action on cemdisiran.
- companySanofi
Dupixent sales growth and profit-share arrangement with Regeneron underpin collaboration revenue strength.
- companyModerna
Shares down 2% in the session; article provides no new Moderna-specific catalyst beyond relative performance.
- companyMerck
Shares up 1% after an October 29 quarterly beat and raised profit outlook, including subcutaneous Keytruda Qlex sales.
- companyPfizer
Shares slightly higher; article references an August 4 quarterly report without new Pfizer-specific developments.
